Castle Biosciences, Inc.
Friendswood, TX
- UEI
- JMKGWGQLA7X7
- CAGE
- 5T5A3
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- SS56A8CVNN59
-
- SAM.gov registration date
- Physical address
- 1500 W Parkwood Ave #400, Friendswood, TX 77546, USA
- Website
- castlebiosciences.com
- Founded
- 2008
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $29,395 |
| FY2025 | $5,550 |
| FY2024 | -$14,450 |
| FY2023 | -$259,600 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $29,395 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Baylor Research Institute | R01DK131951 | $25,730 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Decipher Biosciences, Inc. | San Diego, CA | 621511 Medical Laboratories |
| Genomic Health, Inc. | Redwood City, CA | 621511 Medical Laboratories |
| Mdxhealth, Inc. | Irvine, CA | 621511 Medical Laboratories |
| Biotheranostics Inc. | San Diego, CA | 621511 Medical Laboratories |
| Exact Sciences Laboratories, LLC | Madison, WI | 621511 Medical Laboratories |
About the company
Castle Biosciences, Inc. is a molecular diagnostics company headquartered in Friendswood, Texas, that provides cancer risk-assessment and detection testing services to the Department of Veterans Affairs as a prime contractor on delivery orders under GSA schedules and VA indefinite delivery vehicles. The company operates as a for-profit corporate entity with one named subsidiary, Cernostics Inc., and competes predominantly full-and-open (no set-aside designations across recent awards, with one exception of a Total Small Business set-aside on the most recent delivery order).
Castle Biosciences' federal work centers narrowly on two proprietary diagnostic assays delivered to VA healthcare networks. The DecisionDx-Melanoma test uses 31-gene quantitative PCR expression profiling to predict melanoma recurrence risk; the Predictive Bartlett Esophagus Assay (PBEA) identifies the probability of esophageal cancer development over a five-year period in patients with Barrett's esophagus. Recent representative awards include a $164,395 delivery order from Veterans Integrated Service Network 4 for gene expression profile testing under the Medical Laboratory Testing and Analysis Services GSA Schedule (awarded September 2026, completion August 2027); a $20,000 delivery order from VISN 21 for PBEA (awarded October 2024, completion September 2025); and a $14,450 delivery order from VISN 21 for DecisionDx-Melanoma testing (awarded July 2023). Performance locations include Palo Alto, California and Lebanon, Pennsylvania.
Customer concentration is extreme. The Department of Veterans Affairs accounts for substantially all recent federal work, with VISN 21 alone representing eleven of eighteen total awards and $3.5 million of the $5.2 million combined potential value across the award portfolio (89% of awards by count, 67% of dollars by potential value). VISN 12, VISN 4, VISN 15, and VISN 9 round out the customer set with smaller volumes. Castle Biosciences places task orders under two VA indefinite delivery vehicles — IDC 36C26119D0081 (five task orders) and IDC 36C26121D0108 (four task orders, $23 thousand potential value) — and the GSA Medical Laboratory Testing and Analysis Services schedule. Activity is sparse and irregular: four awards in 2021, declining to two per year in 2022–2024, with one award in 2026. Only one award (the September 2026 VISN 4 delivery order worth $164,395) faces ultimate completion inside the next twenty-four months.
In its limited sub-award footprint, Castle Biosciences acts as a sub-recipient on a February 2024 federal grant from the Baylor Research Institute for stratification of cancer risk in patients with non-dysplastic Barrett's esophagus using the TissueCypher platform (the SCRiBE study). Federal category concentration aligns tightly with the company's diagnostic profile: twelve awards fall under Medical Laboratories (NAICS), five under Testing Laboratories and Services, with seventeen task orders under the Reference Laboratory Testing PSC code. Combined dollars obligated are $246 thousand against $5.2 million potential value, indicating light execution relative to ceiling.
Quick answers
Is Castle Biosciences, Inc. registered in SAM.gov?
Yes. Castle Biosciences, Inc.'s SAM.gov registration is active through August 6, 2027.
Which contract vehicles does Castle Biosciences, Inc. hold?
Castle Biosciences, Inc. holds a place on 1 federal contract vehicle: FSS-621-II.
How much has Castle Biosciences, Inc. received in federal contracts?
Federal contracts obligated $5,550 to Castle Biosciences, Inc. in fiscal year 2025.
What is Castle Biosciences, Inc.'s most recent federal award?
Castle Biosciences, Inc.'s most recent federal contract award is Gene expression profile testing (36C24426F0245), from Veterans Integrated Service Network 4 (VHA), on September 1, 2026.
On GovTribe
See Castle Biosciences, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors